4.78 in After hours! Some (on IV) think it's just a late post but I strongly disagree. A late post would have to have been from the very start of the day and the not posted til 5:00 PM? NOT likely!
IMHO it's a real trade and well justified from items in the SIAL call.
SIAL call today had some very strongly positive comments about SGMO:
"Our research biology business achieved reported and organic growth of 5%, consistent with our full year 2011 organic growth in this area.
This increase was helped by strong demand and growth of our zinc-finger-related products, which grew about 30% in 2011. In 2011, this innovative technology has enabled us to develop novel programs and cell-based assays amongst other products. We have tried to once again to receive the acknowledgment of our peers in Nature Methods' Method of the Year for gene with engineered nucleus.
...
We have a couple of new extensions of our zinc finger platform technologies to share with you. We expanded our capabilities to provide knockout ZFN for rat models that exhibit features key to studying conditions such as obesity, diabetes, atherosclerosis, high cholesterol and hypertension. For many indications, especially metabolic and cardiovascular diseases, the rat is the most suitable model for drug development research. We are the only providers of these rat models, which enable researchers to more accurately predict the efficacy of their drugs and help to strengthen their drug development timelines. This enables our customers to have more certainty about the safety and efficacy of the drugs that move through their pipeline, hopefully making them more successful and profitable.
We also launched our first offering of zinc finger nuclease modified Chinese hamster ovary cell lines. These products are designed for use in the production of biopharmaceuticals and enable customers to reach the market faster and more cost effectively by reducing timelines for early-stage biological drug development. The distinctive features of these cell lines should appeal to organizations to -- looking to build a robust and comprehensive therapeutic protein monoclonal antibody manufacturing platform."
The CHO cell lines will get royalties coming in very quickly. IMHO it won't be as long as most think before SGMO starts turning a profit.
